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ABSTRACT
AIMS: Over half of infants exposed to opioids in utero develop neonatal
abstinence syndrome (NAS) of severity to require pharmacologic therapy.
Current treatments are associated with prolonged hospitalization. We sought to
optimize the dose of sublingual buprenorphine in the treatment of NAS.
DESIGN: Randomized, phase 1, open-label, active-control clinical trial comparing
sublingual buprenorphine to oral morphine.
SETTING: Large, urban, tertiary care hospital.
PARTICIPANTS: Twenty-four term infants with signs and symptoms of NAS.
MEASUREMENTS: Outcomes were neonatal safety, length of treatment, and
length of hospitalization.
FINDINGS: Sublingual buprenorphine was safe and effective. Infants treated
with buprenorphine had a 23-day length of treatment compared to 38 days for
those treated with morphine (p=0.01), representing a 40% reduction. Length of
stay in the buprenorphine group was reduced 24%, from 42 to 32 days (p=0.05).
CONCLUSIONS: Sublingual buprenorphine was safe in NAS, with a substantial
efficacy advantage over standard of care therapy with oral morphine.

INTRODUCTION
Infants born to mothers receiving methadone maintenance often develop
withdrawal symptoms in a complex known as the neonatal abstinence syndrome
(NAS). NAS is characterized by signs and symptoms of CNS hyperirritability,
gastrointestinal dysfunction, respiratory distress, and autonomic symptoms. (1)
Common symptoms in order of frequency include tremors, high-pitched cry,
sneezing, increased muscle tone, regurgitation and vomiting, poor sleep, loose
stools, sweating, excoriation, mottling, nasal stuffiness, low-grade fever, and
tachypnea. NAS reflects a spectrum of disease, and those with milder symptoms
respond well to supportive treatments.(2)

NAS symptoms severe enough to

require pharmacologic treatment occur in 55-94% of infants born to opioiddependent mothers. (1)

The optimal pharmacologic regimen for NAS has not been established, as
reflected in the considerable heterogeneity in the diagnosis (3) and treatment of
NAS among different institutions. (4,5) Treatments employed have included
opioids, anticonvulsants, benzodiazepines, alpha 2 adrenergic antagonists,
chloral hydrate, and the phenothiazine antipsychotic agent chlorpromazine.
Cochrane reviews, (6,7) the American Academy of Pediatrics, (1) and expert
review (8,9) identify opioid replacement as the ideal treatment for the withdrawal
symptoms associated with in utero exposure to opiates. Morphine is the most
commonly used agent, and is associated with treatment duration of 8-79 days,
(10-15) almost always in an inpatient setting. The use of outpatient treatment in

highly selected patients has been reported to be associated with shorter inpatient
stays, but longer total duration of therapy. (16)

Buprenorphine is a long-acting partial mu opioid receptor agonist used in
the treatment of adult abstinence therapy. It has the advantage of decreased
abuse potential and less respiratory depression than other opioid agonists. We
have previously reported the first use of sublingual buprenorphine in NAS at a
dose of 13.2 mcg/kg/day in three divided doses. (17) Though designed as a
phase 1 safety study, the investigation suggested reduction in lengths of
treatment and inpatient hospitalization of approximately 30%. A higher incidence
of phenobarbital adjunctive therapy in the buprenorphine group led us to optimize
dose parameters. We report here on a second cohort of 24 patients treated with
this revised dose schema.
METHODS
Study Design
This was a single site, randomized, open label trial. (Figure 1) Neonates
were randomized to treatment with either sublingual buprenorphine or oral
morphine in a 1:1 ratio. NAS was graded using the MOTHER NAS score, which
is the standard instrument used in the multicenter NIH funded MOTHER study
(ClinTrials.gov ID NCT00271219) of buprenorphine in pregnancy. (18) It is also
the standard instrument at TJUH. The MOTHER NAS score (hereafter “NAS
score”) is based upon the Finnegan score, (19) modifications of which are the
most commonly used to monitor NAS. (5,20) Initiation of treatment was based on

any consecutive 3 scores adding up to ≥ 24. Inclusion criteria included ≥ 37
weeks gestation, exposure to opioids in utero, and demonstration of signs and
symptoms of NAS requiring treatment. Exclusion criteria were major congenital
malformations and/or intrauterine growth retardation, (21) medical illness
requiring

intensification

of

medical

therapy,

concomitant

maternal

benzodiazepine or severe alcohol abuse, maternal use of alcohol or of
benzodiazepines in the 30 days prior to enrollment (as determined by self-report
or intake urine drug screen), concomitant neonatal use of cytochrome P450 3A
inhibitors or inducers prior to treatment, seizure activity or other neurologic
abnormality, breast feeding or inability of mother to give informed consent due to
co-morbid psychiatric diagnosis. The study was approved by the Institutional
Review

Board

of

Thomas

Jefferson

University.

Computer-generated

randomization was performed by the hospital Investigational Drug Service.

Study Treatments
Patients randomized to sublingual buprenorphine initially received 15.9
mcg/kg/day in 3 divided doses. Buprenorphine solution was prepared by mixing
buprenorphine for injection (Buprenex, Reckitt Benckiser) to a final concentration
of 0.075 mg/mL in 100% ethanol USP (30% of total volume) and simple syrup
USP (85 gm sucrose/100 ml). The solution was administered under the tongue
followed by insertion of a pacifier to reduce swallowing. Dose escalation was a
25% increase for NAS scale scores ≥24 total on 3 measures or a single score of
≥12. Patients with inadequate control could be administered a rescue dose of

50% of the previous dose, after which the subsequent dose would be advanced
25%. After at least 3 days of dose stabilization, patients could begin weaning for
scores < 8. Weaning was at intervals of 10%. Cessation of dosing occurred
when buprenorphine was within 10% of the initial dose. All dose calculations
were based upon birth weight.

If NAS was not controlled with maximally

specified dose of 60 mcg/kg/day, patients were administered phenobarbital 20
mg/kg load followed by 2.5 mg/kg twice a day for at least 2 days. Phenobarbital
was weaned prior to reduction of the opioid. When NAS scores were reliably <8,
the daily dose of phenobarbital was reduced by 50%, followed by complete
cessation.

Standard of care treatment at Thomas Jefferson University Hospital
consisted of an initial dose of morphine 0.4 mg/kg/day in 6 divided doses with
dose escalation of 10%/day for NAS scale scores ≥24 total on 3 measures or a
single score of ≥12.

All dose calculations were based upon daily weight.

Adjunctive treatment with phenobarbital was initiated when the dose of morphine
reached 1 mg/kg/day. Weaning from the phenobarbital was the same in both the
buprenorphine and morphine groups.

Infants were weaned with 10% dose

reduction every 24 hours in morphine as tolerated until 0.15 mg/kg/day was
reached. All patients in the trial were observed for at least two days following the
cessation of dosing.

Statistics

This was a follow up pilot study to optimize the dose of sublingual
buprenorphine in neonates.
formal power calculation.

Therefore, sample size was not based upon a

Group comparisons for continuous variables were

made using the Mann-Whitney U test. Statistical analysis was completed with
JMP 5.1.2, (SAS Institute Inc.) Analysis was performed on an intention to treat
basis.

RESULTS
Twenty-four infants were enrolled between March 2008 and January 2010.
Patient characteristics are presented in Table 1.

Safety
A list of all adverse events observed in the trial is presented in Table 2.
There was one serious adverse event in a patient randomized to buprenorphine.
This infant randomized to buprenorphine had adverse events of CMV infection,
prolonged reflux/poor feeding, elevated transaminases, aminoaciduria, and
paronychia of a finger. Poor feeding and enteral hypomotility was initially thought
to be part of NAS, but lack of resolution on buprenorphine and phenobarbital,
and indeed no worsening when these drugs were removed led to further medical
evaluation. CMV was noted in urine, and a lack of cerebral calcifications or
microcephaly at birth suggest a late in utero or possibly nosocomial infection.
Length of buprenorphine treatment was 45 days and length of stay was 98 days.
On the last day of buprenorphine weaning, alanine transaminase (ALT) was

noted to be 30x the upper limit of normal (ULN), while aspartate transaminase
(AST) was noted to be 20x ULN. These values waxed and waned over the
remainder of the hospitalization, and remained elevated 6 weeks following the
cessation of buprenorphine. Bilirubin was never elevated. The DSMB reviewed
the case and came to the unanimous judgment that buprenorphine was not
responsible for the clinical course of the infant, but did endorse our suggestion to
monitor liver function for future enrollees. Liver function testing pre-dose, and at
7 and 21 days post randomization was normal in 6 subsequent patients (three in
each treatment arm).

Efficacy
Infants treated with buprenorphine had a 23-day length of treatment
compared to 38 days for those treated with morphine (p=0.01). (Table 3 and
Figure 2) This represents a 40% reduction. Length of stay in the buprenorphine
group was reduced 24%, from 42 to 32 days (p=0.05). Three infants treated with
buprenorphine required phenobarbital compared to one infant treated with
morphine.

DISCUSSION
This study builds upon our prior report describing the use of
buprenorphine in the treatment of opioid NAS.

The goal of the current

investigation was to optimize buprenorphine dosing by increasing the 1) initial
dose, 2) rate of dose up-titration, and 3) maximum daily dose. An increase in

stock drug concentration was used to maintain manageable drug volume for
administration. Sublingual buprenorphine continued to maintain safety at these
higher doses.

In addition, there was continued advantage over morphine in

length of treatment and length of stay, which was now statistically significant. It
is arguable that many signs and symptoms observed in the infant with CMV
infection did not reflect severity of NAS but instead were manifestations of the
multiorgan viral process.

Data from this infant was included in the primary

analysis. However, removal of this infant causes the length of treatment to drop
from 23 to 21 days, and length of stay to drop from 32 to 26.
Three patients in the buprenorphine group required the use of adjunctive
phenobarbital compared to one patient in the morphine group. Phenobarbital is
often used as a rescue therapy when maximum opioid replacement therapy dose
is reached without adequate resolution of symptoms. It has also been used as
an initial adjunct in combination therapy with an opioid (12) or as initial
monotherapy. (22)

Morphine and buprenorphine employ different up-titration

rates and number of up-titrations until maximum dose is reached (6 for
buprenorphine and 9 for morphine). Thus, the need for adjunctive phenobarbital
is not necessarily a surrogate of “treatment failure” in infants with a more severe
withdrawal symptom complex. Phenobarbital arguably has a therapeutic index
similar to that of opioid treatment in this patient population. It is also not clear
where on the dose response curve the present maximum buprenorphine dose
lies. Thus it is possible as a partial agonist, buprenorphine may not be able to
induce the dense signal generation at the mu opioid receptor obtained with

morphine. Alternatively, it could be hypothesized that a higher maximum dose of
buprenorphine could reduce the frequency with which adjunctive phenobarbital
would need to be used. However, as there are no definitive adverse events
associated with short-term exposure to phenobarbital, it is possible that a short
course of phenobarbital may be a useful adjunct to reduce total duration of
treatment in children with more severe withdrawal symptoms.
A mechanistic basis for the improvement of buprenorphine over morphine
is not immediately clear. The longer duration of action and residence at the mu
opioid receptor of buprenorphine relative to morphine may reduce the sudden
shifts in receptor agonism and withdrawal symptoms.

A more prolonged

persistence of drug effect following cessation likely reduces symptoms. Two
features of buprenorphine dosing compared to morphine also merit noting.
Buprenorphine has a more rapid up-titration of dose compared to morphine,
which may allow a quicker attainment of symptom control.

Though both

regimens employ a 10% weaning schedule, buprenorphine is stopped when a
dose within 10% of the starting dose. In contrast, the initial morphine dose is 0.4
mg/kg/day, while cessation of dosing takes place only after drug has been
weaned to 0.15 mg/kg/day. Finally, the buprenorphine group dosing was based
upon birth weight, while the morphine group was dosed according to daily weight.
This difference serves to decrease a relative dose of buprenorphine as the infant
grows.
This study was of an open label, randomized, design with primary goals of
demonstrating safety and feasibility of sublingual buprenorphine. It is possible

that there was occult bias in the scoring of infants by the nurse evaluators,
despite the use of structured training sessions. A double blind, double dummy
study would be required to fully evaluate any differential efficacy of
buprenorphine over morphine.

Another limitation is that the study excluded

infants with benzodiazepine exposure and preterm infants. These exclusions
serve to limit the generalizability of results. Infants with in utero benzodiazepine
exposure have a longer length of stay and treatment compared to those without.
(15,23-25)
directed.

These infants represent a group in whom research should be
Premature infants typically have less severe NAS, (26) but

buprenorphine does not have an established safety record in this population.
Finally, while the length of treatment and length of stay noted is this study is
consistent with observational data at Thomas Jefferson University Hospital
between 2000-2006, (15) it is longer than has been noted at other institutions.
(10,13,27,28) It is not clear if the magnitude of advantage over standard therapy
would be maintained at institutions with a shorter length of stay.
In conclusion, buprenorphine at an optimized dose schema has been
demonstrated to be safe and efficacious in the treatment of NAS.

While

indications of a therapeutic advantage over morphine again have been
demonstrated, these need to be verified in a double blind clinical trial.
Additionally, the unique characteristics of buprenorphine make exploration of
outpatient use for treatment of NAS a ripe area for clinical research.
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Table 1. Characteristics of Patients in the trial

N
Sex
Race

Birth weight (gm)
Gestational Age
(weeks) ║
Onset of
Treatment. Mean
Days after birth ║
1-Minute APGAR
Score ║
5-Minute APGAR
Score ║
Daily Maternal
Methadone Dose
(mg)
║
Mean

Male
Female
White, non
Hispanic
AfricanAmerican

Morphine
12
4
8
11

Buprenorphine
12
6
6
12

1

0

3010
39.3

2680
39.1

2.4 [SD 0.89]

2.3 [SD 1.4]

8.1

7.6

8.9

9.0

124 [SD 60]

157 [SD 57]

Table 2 : Efficacy Outcomes of Buprenorphine and Neonatal Opium
Solution Mean

N
Length of Treatment (days)
Length of Stay (days)
Phenobarbital adjunctive
therapy (patients)

Buprenorphine
12
23 [SD 12]
32 [SD 24]
3

Morphine
12
38 [SD 14]
42 [SD 13]
1

p value
0.01
0.05

Table 3: Adverse Events
Subject
Treatment
Allocation
Number
039
morphine

047

049
050
051
052

Adverse Event

oral thrush
paronychia of finger
reflux/poor feeding

elevated
transaminases
Cytomegalovirus
infection
aminoaciduria
morphine
conjunctivitis
morphine
oral thrush
buprenorphine clavicle birth fracture
morphine
reflux
buprenorphine

Serious Causality
AE
no
no
yes

no

unrelated
unrelated
probably not
related
probably not
related
unrelated

no
no
no
no
no

unrelated
unrelated
unrelated
unrelated
unrelated

no

Figure 1: Study Schema

Screening
Inclusion
• >37 weeks gestation
• In utero exposure to opioids
• Need for pharmacologic therapy
for NAS

•
•
•

Exclusion
Exposure to benzodiazepines
Medical illness
Breastfeeding

Randomization

Buprenorphine 15.9 mcg/kg in 3
divided doses
• Increase dose 25% until symptoms
controlled
• Phenobarbital added when dose
reaches 60 mcg/kg/day

Morphine 0.4 mg/kg/day in 6 divided
doses
• Increase dose 10% until symptoms
controlled
• Phenobarbital added when dose
reaches 1 mg/kg/day

Wean dose 10% per day as tolerated

Wean dose 10% per day as tolerated

Cessation of therapy when within
10% of initial dose

Cessation of therapy at 0.15
mg/kg/day

2 days observation prior to discharge

Figure 2: Length of Treatment and Length of Stay
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